{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:53Z","timestamp":1786122113087,"version":"build-2736575974"},"reference-count":33,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Delayed relapse after curative-intent treatment remains difficult to explain and predict in human papillomavirus (HPV)-associated cervical cancer, including after periods of sustained remission with undetectable circulating tumor DNA (ctDNA) or circulating HPV DNA. This limitation of tumor-centered surveillance demands the evaluation of immune parameters alongside tumor-derived biomarkers. We propose \u201cimmune absence\u201d as a hypothesis-generating, operational framework referring to the sustained reduction or non-persistence of pre-specified tumor-reactive T-cell receptor (TCR) clonotypes in serial peripheral blood samples, obtained during minimal residual disease states in which antigen exposure may be limited or intermittent. We hypothesize that this longitudinal pattern may precede molecular or clinical evidence of relapse in a subset of patients and coexist with established mechanisms, such as tumor evolution, immune escape, T-cell dysfunction, and therapeutic resistance. Integrating serial ctDNA or circulating HPV DNA measurements with tumor-reactive TCR clonotype dynamics may provide complementary information on residual tumor burden and the persistence of circulating tumor-reactive T-cell responses. Peripheral blood TCR non-detection does not establish complete loss of anti-tumor immunity and may reflect compartmentalized immunity, clonal replacement, antigenic evolution, or assay limitations. Prospective longitudinal studies are required to establish the prognostic value of this framework before clinical use.<\/jats:p>","DOI":"10.3390\/cancers18162530","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:01:36Z","timestamp":1786089696000},"page":"2530","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Absence as a Proposed Framework for Delayed Relapse After Curative-Intent Treatment in Human Papillomavirus-Associated Cervical Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Norihito","family":"Kamo","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Soeda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"},{"name":"Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Iwaki City Medical Center, Iwaki 973-8555, Japan"},{"name":"Department of Community Obstetrics and Gynecology Support, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"},{"name":"Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2025.03.002","article-title":"Prognostic value of assessing ctDNA in patients with endometrial carcinoma\u2013An international multicenter study","volume":"195","author":"Lindemann","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease\u2014Latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-21-0625","article-title":"Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer","volume":"27","author":"Jeannot","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.23.00954","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1158\/1078-0432.CCR-25-0512","article-title":"Surgical and blood-based minimal residual disease in patients with ovarian cancer after first-line therapy: Clinical outcomes and translational opportunities","volume":"31","author":"Knisely","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101850","DOI":"10.1136\/ijgc-2024-005692","article-title":"Outcomes of minimal residual disease at upfront debulking surgery compared with complete cytoreduction after neoadjuvant chemotherapy","volume":"35","author":"Romero","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u201cT cell exhaustion\u201d","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ygyno.2020.11.009","article-title":"Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease","volume":"160","author":"Morse","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41423-023-01064-3","article-title":"Regulation of CD8+ T memory and exhaustion by the mTOR signals","volume":"20","author":"Chen","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ni.2018","article-title":"Normal T cell homeostasis: The conversion of naive cells into memory-phenotype cells","volume":"12","author":"Sprent","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zander, R., Khatun, A., Schauder, D.M., and Cui, W. (2018). Transcriptional and epigenetic regulation of effector and memory CD8 T cell differentiation. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02826"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding subset diversity in T cell memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nenclares, P., Larkeryd, A., Manodoro, F., Lee, J.Y., Lalondrelle, S., Gilbert, D.C., Punta, M., O\u2019Leary, B., Rullan, A., and Sadanandam, A. (2024). T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1296948"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41698-024-00637-3","article-title":"Cellular heterogeneity and key subsets of tissue-resident Memory T Cells in cervical cancer","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brachy.2023.10.007","article-title":"Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy","volume":"23","author":"Manzar","year":"2024","journal-title":"Brachytherapy"},{"key":"ref_25","first-page":"267","article-title":"Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor","volume":"9","author":"Pilch","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"238ra70","DOI":"10.1126\/scitranslmed.3008211","article-title":"Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients","volume":"6","author":"Cha","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","article-title":"Tissue-resident T cells and other resident leukocytes","volume":"37","author":"Masopust","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","article-title":"Exhaustion and senescence: Two crucial dysfunctional states of T cells in the tumor microenvironment","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2451093","DOI":"10.1002\/eji.202451093","article-title":"Characteristics and mechanisms of T-cell senescence: A potential target for cancer immunotherapy","volume":"54","author":"Wu","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0148021","DOI":"10.1128\/spectrum.01480-21","article-title":"Detection of circulating HPV16 DNA as a biomarker for cervical cancer by a bead-based HPV genotyping assay","volume":"10","author":"Galati","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2022.07.028","article-title":"Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer","volume":"167","author":"Sivars","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gu, Y., Wan, C., Qiu, J., Cui, Y., Jiang, T., and Zhuang, Z. (2020). Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0224001"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2530\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:14:54Z","timestamp":1786090494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":33,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162530"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162530","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}